Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback